These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26424521)

  • 41. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea.
    Wills PJ; Hall RL; Chan W; Cole PJ
    J Clin Invest; 1997 Jan; 99(1):9-13. PubMed ID: 9011581
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists.
    Porter DW; Bradley M; Brown Z; Charlton SJ; Cox B; Hunt P; Janus D; Lewis S; Oakley P; O'Connor D; Reilly J; Smith N; Press NJ
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3285-90. PubMed ID: 24974342
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term treatment with theophylline reduces neutrophils, interleukin-8 and tumor necrosis factor-alpha in the sputum of patients with chronic obstructive pulmonary disease.
    Iiboshi H; Ashitani J; Katoh S; Sano A; Matsumoto N; Mukae H; Nakazato M
    Pulm Pharmacol Ther; 2007; 20(1):46-51. PubMed ID: 16413994
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neutrophil-mediated degradation of lung proteoglycans: stimulation by tumor necrosis factor-alpha in sputum of patients with bronchiectasis.
    Shum DK; Chan SC; Ip MS
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1925-31. PubMed ID: 11069836
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reduction of neutrophilic lung inflammation by inhalation of the compatible solute ectoine: a randomized trial with elderly individuals.
    Unfried K; Krämer U; Sydlik U; Autengruber A; Bilstein A; Stolz S; Marini A; Schikowski T; Keymel S; Krutmann J
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2573-2583. PubMed ID: 27799756
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor Necrosis Factor, but Not Neutrophils, Alters the Metabolic Profile in Acute Experimental Arthritis.
    Oliveira MC; Tavares LP; Vago JP; Batista NV; Queiroz-Junior CM; Vieira AT; Menezes GB; Sousa LP; van de Loo FA; Teixeira MM; Amaral FA; Ferreira AV
    PLoS One; 2016; 11(1):e0146403. PubMed ID: 26742100
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhaled fluticasone in bronchiectasis: a 12 month study.
    Tsang KW; Tan KC; Ho PL; Ooi GC; Ho JC; Mak J; Tipoe GL; Ko C; Yan C; Lam WK; Chan-Yeung M
    Thorax; 2005 Mar; 60(3):239-43. PubMed ID: 15741443
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models.
    Ha H; Debnath B; Odde S; Bensman T; Ho H; Beringer PM; Neamati N
    J Chem Inf Model; 2015 Aug; 55(8):1720-38. PubMed ID: 26153616
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Laboratory and clinical evaluation of the mucolytic properties of acetylcysteine.
    Hurst GA; Shaw PB; LeMaistre CA
    Am Rev Respir Dis; 1967 Nov; 96(5):962-70. PubMed ID: 6059205
    [No Abstract]   [Full Text] [Related]  

  • 50. The selective CXCR2 antagonist SB272844 blocks interleukin-8 and growth-related oncogene-alpha-mediated inhibition of spontaneous neutrophil apoptosis.
    Glynn PC; Henney E; Hall IP
    Pulm Pharmacol Ther; 2002; 15(2):103-10. PubMed ID: 12090783
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
    Garau A; Bertini R; Mosca M; Bizzarri C; Anacardio R; Triulzi S; Allegretti M; Ghezzi P; Villa P
    Eur Cytokine Netw; 2006 Mar; 17(1):35-41. PubMed ID: 16613761
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases.
    Richman-Eisenstat JB; Jorens PG; Hébert CA; Ueki I; Nadel JA
    Am J Physiol; 1993 Apr; 264(4 Pt 1):L413-8. PubMed ID: 8476069
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals.
    Gordon JR; Li F; Zhang X; Wang W; Zhao X; Nayyar A
    J Leukoc Biol; 2005 Dec; 78(6):1265-72. PubMed ID: 16204619
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IL-17A promotes the exacerbation of IL-33-induced airway hyperresponsiveness by enhancing neutrophilic inflammation via CXCR2 signaling in mice.
    Mizutani N; Nabe T; Yoshino S
    J Immunol; 2014 Feb; 192(4):1372-84. PubMed ID: 24446518
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Innate immune activation in neutrophilic asthma and bronchiectasis.
    Simpson JL; Grissell TV; Douwes J; Scott RJ; Boyle MJ; Gibson PG
    Thorax; 2007 Mar; 62(3):211-8. PubMed ID: 16844729
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists.
    Ho KK; Auld DS; Bohnstedt AC; Conti P; Dokter W; Erickson S; Feng D; Inglese J; Kingsbury C; Kultgen SG; Liu RQ; Masterson CM; Ohlmeyer M; Rong Y; Rooseboom M; Roughton A; Samama P; Smit MJ; Son E; van der Louw J; Vogel G; Webb M; Wijkmans J; You M
    Bioorg Med Chem Lett; 2006 May; 16(10):2724-8. PubMed ID: 16540318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical value of liquifying drugs of bronchial secretions].
    Molina C; Aiache JM; Pradelle J; Brun J; Cheminat JC
    Poumon Coeur; 1970; 26(1):91-102. PubMed ID: 4393035
    [No Abstract]   [Full Text] [Related]  

  • 58. Blockade of CXCR2 signalling: a potential therapeutic target for preventing neutrophil-mediated inflammatory diseases.
    Boppana NB; Devarajan A; Gopal K; Barathan M; Bakar SA; Shankar EM; Ebrahim AS; Farooq SM
    Exp Biol Med (Maywood); 2014 May; 239(5):509-18. PubMed ID: 24625439
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases.
    Russo RC; Garcia CC; Teixeira MM; Amaral FA
    Expert Rev Clin Immunol; 2014 May; 10(5):593-619. PubMed ID: 24678812
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of erythromycin on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum.
    Shibuya Y; Wills PJ; Cole PJ
    Respiration; 2001; 68(6):615-9. PubMed ID: 11786718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.